help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
The Oncologist, Vol. 2, No. 4, 275–275, August 1997
© 1997 AlphaMed Press

SPECIAL SECTION
PATIENT CARE

Dispatches from: The New York City Post, The Houston Post

Correspondence: For more information, or for patient referral, contact Dr. Charles Hesdorffer at telephone: 212-305-4907, or e-mail: hesdorffer{at}cuccfa.ccc.columbia.edu or Dr. David Savage at telephone: 212-305-9783, or e-mail: savage{at}cuccfa.ccc.columbia.edu

The Patient Care section of The Oncologist extends the opportunity for major cancer centers to enroll patients in high-priority clinical trials. If you wish to have your clinical trial(s) announced, send all pertinent details to the Executive Editor.


   Dispatches from:
Top
 Dispatches from:
 
THE NEW YORK CITY POST
Columbia-Presbyterian Medical Center in New York offers an extensive program in allogeneic and autologous stem cell transplantation, including protocols for:

{blacktriangleup} Poor-risk Hodgkin’s and non-Hodgkin’s lymphoma, including patients with high-risk features at diagnosis (e.g., bulky disease, adverse histology), chemoresistant disease, and relapse.
{blacktriangleup} Small cell and non-small cell lung cancer, either at diagnosis prior to treatment or in patients with chemoresponsive disease.
{blacktriangleup} Brain tumors, including patients with newly diagnosed glioblastoma, as well as recurrent anaplastic astrocytomas and oligodendrogliomas.
{blacktriangleup} Breast cancer, including patients with metastatic disease.
{blacktriangleup} Multiple myeloma.
{blacktriangleup} Ovarian cancer.
{blacktriangleup} MDR gene therapy for patients with stage 4 breast cancer, brain tumors and ovarian cancer entering other institutional high-dose protocols.
{blacktriangleup} CD34 cell selection and purging for patients with myeloma and lymphoma.
{blacktriangleup} Immunotherapy for patients with breast cancer post-transplantation.

THE HOUSTON POST
New therapies available at M.D. Anderson Cancer Center now can be found on the World Wide Web.

Cancer patients wanting cutting-edge therapy or whose disease no longer responds to traditional treatment may find new hope on the "information superhighway."

The University of Texas M.D. Anderson Cancer Center has posted its clinical trials available for cancer patients on a World Wide Web site at: www.clinicaltrials.org. The information, and a variety of additional information, also may be located through M.D. Anderson’s home page on the World Wide Web at www.mdanderson.org.

"Clinical research studies offer patients cancer treatments they otherwise could not receive and usually result in improved therapies," says Dr. Leonard Zwelling, Associate Vice President for Clinical and Translational Research. Dr. Zwelling explained that in cancer research, a clinical trial generally refers to evaluating new treatment methods such as surgery, drugs or radiation techniques, although methods of prevention, detection or diagnosis also may be the subject of such studies.

Currently, more than 200 clinical trials open for enrollment are posted for easy access to patients. Treatments available can be viewed by cancer type (for example, breast cancer or prostate cancer), by name of the physician conducting the study, or by the treatment agent(s) being used in the study.

The URL is: www.clinicaltrials.org


   FOOTNOTES
Top
 Dispatches from:
 
To become or refer a patient: Patients call: 800-392-1611 #2 (in U.S.), or 713-792-6161 #2 (outside the U.S.); referring physicians call: 800-392-1611 #1 (in U.S.), or 713-792-6161 #1 (outside the U.S.).

Look for our expanded coverage on clinical trials in future Patient Care sections of The Oncologist.





This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS